Supercharged immune cells take on hard-to-treat cancers
NCT ID NCT06198296
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new type of immunotherapy for adults with solid tumors that have a protein called GPC3 on their surface. Researchers take a patient's own T cells, add genes to help them recognize and attack GPC3-positive cancer cells, and also include a safety switch to stop the cells if needed. The main goal is to check safety and find the right dose in 21 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EMBRYONAL SARCOMA OF LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Houston Methodist Hospital
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- A new test could reveal how radiation affects the liver